Brief: Karuna Therapeutics Announces The Lancet Publication Of Data From Phase 3 Emergent-2 Trial Evaluating Karxt In Schizophrenia
14/12/2023 23:38
Dec 14 (Reuters) - Karuna Therapeutics Inc KRTX.O :
* KARUNA THERAPEUTICS ANNOUNCES THE LANCET PUBLICATION OF
DATA
FROM PHASE 3 EMERGENT-2 TRIAL EVALUATING KARXT IN SCHIZOPHRENIA
* KARUNA THERAPEUTICS INC - KARXT WAS GENERALLY WELL
TOLERATED
Source text for Eikon: ID:nBwn0dX1a
Further company coverage: KRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Karuna Therapeutics
See all newsMoody's says pharma outlook turns 'positive' on GLP-1 drug push
Brief: Karuna Therapeutics Says Complaint Was Filed By Karuna Stockholder Seeking To Enjoin Proposed Merger With Bristol-Myers Squibb
Karuna Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Karuna Therapeutics Inc expected to post a loss of $2.65 a share - Earnings Preview
Bristol Myers posts better-than-expected 4th-quarter results (updated)